Anti-CD19 CAR T cells potently redirected to kill solid tumor cells

Area of Science:

• Oncology
• Immunotherapy
• Biotechnology

Background:

• CAR T-cell therapy shows promise but faces challenges in solid tumors, including T-cell expansion, persistence, and safe antigen targeting.
• Current strategies often struggle to achieve sufficient T-cell fitness and tumor-specific activity for effective solid tumor treatment.

Purpose of the Study:

• To develop an innovative CAR T-cell therapy platform that enhances expansion, persistence, and tumor-specific cytotoxicity for solid tumors.
• To engineer CAR T-cells that can overcome common limitations in solid tumor treatment by leveraging a secreted bridging protein.

Main Methods:

• Development of a chimeric antigen receptor (CAR) T-cell targeting CD19, engineered to secrete a bispecific bridging protein.
• The bridging protein binds to CD19 on T-cells and tumor antigens (e.g., Her2) on cancer cells, facilitating targeted T-cell engagement.
• In vitro and in vivo studies were conducted to evaluate the efficacy, expansion, and persistence of the engineered CAR T-cells.

Main Results:

• The engineered CAR T-cells demonstrated potent cytotoxicity against Her2-positive tumor cells in vitro and in vivo.
• The strategy effectively utilizes CD19 expression on normal B cells to promote CAR T-cell expansion, persistence, and fitness.
• The secreted bridging protein's short half-life ensures selective accumulation at tumor sites with high antigen expression.

Conclusions:

• Antigen-bridging CAR T-cells represent a versatile platform for treating solid tumors by enhancing T-cell function and enabling targeted tumor cell killing.
• This approach offers a promising strategy to overcome key hurdles in CAR T-cell therapy for a wide range of cancers.